Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2681-2688

  Ghirardi, Orlando ^a   Lo Giudice, Pietro ^a   Pisano, Claudio ^a   Vertechy, Mario ^a   Bellucci, Augusta ^a   Vesci, Loredana ^a   Cundari, Sante ^a   Miloso, Mariarosaria ^b   Rigamonti, Laura Maria ^b   Nicolini, Gabriella ^b   Zanna, Claudio ^a   Carminati, Paolo ^a  

^a Sigma Tau SpA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Acetyl L carnitine; Neurotoxicity; Oxaliplatin

Indexed keywords

LEVACECARNINE; OXALIPLATIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHRONIC DISEASE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SENSORY NERVE CONDUCTION;

ACETYLCARNITINE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHRONIC DISEASE; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HT29 CELLS; HUMANS; MALE; MICE; MICE, NUDE; NEUROPROTECTIVE AGENTS; ORGANOPLATINUM COMPOUNDS; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, WISTAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22944485043     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Tashiro T, Kawada Y, Sakurai Y and Kidani Y: Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother 43: 251-260, 1989.
2. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cviktovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL and Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
3. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzaki M, Merger G, N'Daw D, Vigoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF and Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996.
4. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I and Fabbrica D: Morphometric study of the sensory neurones and peripheral nerve changes induced by chronic cisplatin (DDP) administration. Acta Neuropathol 84: 364-371, 1992.
5. Cavaletti G, Minoia C, Schieppati M and Tredici G: Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Rad Oncol Biol Phys 29: 771-776, 1994.
6. McKeage MJ, Boxall FE, Jones M and Harrap KR: Lack of neurotoxicity of oral bisacetatoammine-dichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54: 629-631, 1994.
7. Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD and Chaney SG: Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46: 342-351, 1998.
8. Cavaletti G, Fabbrica D, Minoia C, Frattola L and Tredici G: Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9: 443-447, 1998.
9. Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M and Griffon-Etienne G: Effect of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37: 2457-2463, 2001.
10. Fritz IB: Carnitine and its role in fatty acid metabolism. Adv Lipid Res 1: 285-334, 1963.
11. Bremer J: Carnitine metabolism and functions. Physiol Rev 63: 1420-1480, 1983.
12. Stanley CA: New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv Pediatr 34: 59-88, 1987.
13. Bieber LL: Carnitine. Annu Rev Biochem 57: 261-283, 1988.
14. Lowitt S, Malone JI, Salem AF, Korthals J and Benford S: Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44: 677-680, 1995.
15. Di Giulio AM, Lesma E and Gorio A: Diabetic neuropathy in the rat: 1. ALC augments the reduced levels and axoplasmic transport of substance P. J Neurosci Res 40: 414-419, 1995.
16. Kano M, Kawakami T, Hori H, Hashimoto Y, Tao Y, Ishikawa Y and Takenaka T: Effects of ALC on the fast axoplasmic transport in cultured sensory neurons of streptozotocin-induced diabetic rats. Neurosci Res 33: 207-213, 1999.
17. Fernandez E, Pallini R, Tamburrini G, Lauretti L, Tancredi A and La Marca F: Effects of levo-acetylcarnitine on second motoneuron survival after axotomy. Neurol Res 17: 373-376, 1995.
18. Aley KO, Reichling DB and Levin JD: Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neurosci 73: 259-265, 1996.
19. Taiwo YO, Coderre TJ and Levine JD: The contribution of training to sensitivity in the nociceptive paw-withdrawal test. Brain Res 487: 148-151, 1989.
20. Cavaletti, G, Minoia C, Schieppati M and Tredici G: Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Rad Oncol Biol Phys 29: 771-776, 1994.
21. Tredici G, Cavaletti G, Petruccioli MG, Fabbrica D, Tedeschi M and Venturino P: Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology 75: 701-704, 1994.
22. Skehan P, Stoneng R, Scudiero D, Monks A, Mc Mahon J, Vistica D, Warren JT, Bokesch H, Kennedy S and Booyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
23. Piovesan P, Pacifici L, Taglialatela G, Ramacci MT and Angelucci L: Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res 633: 77-82, 1994.
24. Foreman PJ, Perez-Polo JR, Angelucci L, Ramacci MT and Taglialatela G: Effect of acetyl-L-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. Prog Neuropsychopharmacol Biol Psychiatry 19: 117-133, 1995.
25. Fanti L, Berloco M and Pimpinelli S: Carnitine suppression of position-effect variegation in Drosophila melanogaster. Mol Gen Genet 244: 588-595, 1994.
26. Pomponi MG and Neri G: Butyrate and acetyl-1-carnitine inhibit the cytogenetic expression of the fragile X in vitro. Am J Med Gen 57: 447-450, 1994.
27. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P and Cavaletti G: Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9: 5756-5767, 2003.